REYKJAVIK, ICELAND (June 26, 2025) - Alvotech SA (NASDAQ: ALVO, ALVO SDB), a global biotech company known for developing and manufacturing biosimilar medicines, has announced a reduction in the interest rate on its senior secured term loan facility. This agreement, made with its lenders, including GoldenTree Asset Management, will decrease Alvotech's interest payments by an estimated $8.2 million over the next year. The facility, originally consisting of two tranches totaling $965 million, has been restructured into a single tranche with a lower interest rate of SOFR plus 6.0% per annum. The move reflects Alvotech's improved financial performance and investor confidence in its future growth and product launches. As of June 25, 2025, the facility's balance stands at approximately $1,081 million, with a cash balance of around $152 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.